Clinical trials: Steatotic Liver Disease
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
AGED Diagnostics Clinical Validation Study
Validation of Blood-Based Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis: This study aims to validate two investigational blood tests developed by AGED Diagnostics for the…
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Fibrosis and Cirrhosis of Liver, MetALD
- Trial name
- NCT07867574
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
- Trial name
- NCT06419374
- Testing
- Pegozafermin
- Where
- 330 sites in United States, Argentina and 23 more
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Metabolic Dysfunction-associated Steatohepatitis
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
This study is a multicenter, open-label, dose-escalation trial designed to evaluate the safety, tolerability, PK, and PD profiles of ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07462455
- Testing
- ACT500 tablets
- Where
- 4 sites in China
- Volunteers
- 24 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Metabolic Dysfunction-Associated Steatoic Liver Disease
A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic stress-related liver injury closely associated with insulin resistance, with a global prevalence of approximately 25%.
- Trial name
- NCT07878091
- Testing
- Kylo 0603 Capsule 8mg, Kylo 0603 Capsule 12mg, Kylo 0603 Capsule 16mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Metabolic Dysfunction-associated Steatotic Liver Disease
Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity.
- Trial name
- MYO-MASLD (NCT06506513)
- Testing
- High-intensity interval training, Moderate intensity exercise training, Low intensity exercise training
- Where
- 2 sites in Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease
This prospective, single-center pilot study will evaluate metabolic flux dysregulation in adults with obesity and suspected or confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) who are scheduled for…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Obesity, Bariatric Surgery
- Trial name
- MASLD (NCT07760909)
- Testing
- Bariatric surgery, Stable isotope tracer infusion, MRI/MRE
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis, Advanced Fibrosis, Sarcopenia
- Trial name
- EPSOMIP2 (NCT07312136)
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Metabolic Dysfunction-Associated Steatotic Liver Disease
The Impact of Nutrition Education and Rice Bran Supplementation on Metabolic Dysfunction-associated Steatotic Liver Disease
This study aims to evaluate the effects of nutrition education with or without rice bran supplementation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07524621
- Testing
- Nutrition Education, Rice Bran
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Shih Chien University
Lean MASLD
Prevalence of Obesity in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Our study will assess the prevalence of obesity among patients with (MASLD) and to evaluate the characteristics of lean MAFLD patients.
- Trial name
- LeanMASLD (NCT07451366)
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assiut University
MASLD
Structured Physical Activity Intervention in Patients With MASLD Receiving a Mediterranean Diet
Lifestyle interventions based on diet and physical activity are the cornerstone of management for metabolic dysfunction-associated steatotic liver disease (MASLD), yet individual responses remain highly variable.
- Trial name
- EHMet-DIA (NCT07478588)
- Testing
- Exercise plus Mediterranean diet, At-home exercise plus Mediterranean diet
- Where
- 2 sites in Spain
- Volunteers
- 96 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Alcohol-Related Liver Disease
A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease.
- Trial name
- NCT07450144
- Testing
- LLM-based chatbot, Telephone counseling, Alcohol Brief Intervention
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Liver Steatosis, MASH
Acceptability and Feasibility of a New Approach to Engage Patients With Steatotic Liver Disease in Physical Activity
Steatosis is the building of fat in the liver. Steatotic liver disease (SLD) regroups MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) i.e.
- Conditions
- Liver Steatosis, MASH, MASLD
- Trial name
- NCT06446908
- Testing
- Telehealth coaching for liver disease
- Volunteers
- 12 people
- Sponsor
- Hopital Montfort
Heterozygous Familial Hypercholesterolemia
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
- Trial name
- STEATO-FH (NCT06634160)
- Testing
- Fibroscan, Sample collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital
Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8…
- Conditions
- Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
- Trial name
- NCT07807059
- Testing
- HRS-4729
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Study on the Function of Taiwan Green Propolis in Reducing Blood Lipids and Body Fat in Sub-healthy Groups: MASLD
This study investigates the effectiveness of Taiwanese green propolis in reducing blood lipids and body fat in sub-healthy individuals.
- Trial name
- TGP (NCT07114926)
- Testing
- Taiwanese green propolis
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kuo,HSIN-YU
Hyperinsulinemia, Insulin Resistance
Effect of Insulin Lowering on Lipogenesis
The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver…
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
- Trial name
- NCT07403604
- Testing
- Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Columbia University
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease
- Trial name
- NCT06465186
- Testing
- Efinopegdutide
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
MASLD, Pediatric
Ultrasound-Based Estimation of Hepatic Steatosis in Pediatric MASLD
The purpose of this study is to validate an artificial intelligence (AI)-based algorithm that estimates hepatic steatosis using ultrasound (US) B-mode images in pediatric participants with metabolic dysfunction-associated…
- Trial name
- NCT07265011
- Testing
- Ultrasound and MRI
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jae Won Choi